Funding for this research was provided by:
Saskatchewan Health Research Foundation (4729)
Text and Data Mining valid from 2019-12-01
Received: 12 August 2019
Accepted: 29 September 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: Informed consent will be obtained from all study participants prior to enrolment. This study, including the participant consent form, has received ethical approval from the University of Saskatchewan Biomedical Research Ethics Board (BIO-REB 1019).
: Not applicable; study protocol only.
: FLG declares no competing interests. CDE receives research funding from the Canadian Institutes of Health Research and the Saskatchewan Health Research Foundation. KBK has received funding for the Saskatchewan MS Drugs Research Program from the Saskatchewan Ministry of Health. HJL declares no competing interests. MCL has received educational and/or consulting funding from Biogen Idec, Pendopharm, and Sanofi Genzyme. SJD receives research funding from the Saskatchewan Health Research Foundation and the Saskatchewan Centre for Patient-Oriented Research.